洪明秀

MS Hung 2洪明秀  研究員/副所長
生技與藥物研究所
Email: mhung@nhri.edu.tw

 

EDUCATION

  • Ph.D., Cell and Developmental Biology, Rutgers University, USA (1997)
  • M.S., Marine Biology, National Sun Yat-Sen University, Taiwan (1987)
  • B.S., Zoology, National Taiwan University, Taiwan (1985)

PROFESSIONAL EXPERIENCES

  • Associate Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2023/1- present)
  • Acting Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes ( 2022/11-2022/12)
  • Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2022- present)
  • Associate Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2017/09-2020/08；2020/11- present)
  • Acting Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes ( 2020/09-2020/10)
  • Associate Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2011- 2022)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2004-2011)
  • Postdoctoral Fellow, Institut Pasteur, Paris, France (2002-2004)
  • Chercheur Associé, CNRS, France (2003)
  • Postdoctoral Fellow, Institute of Molecular Biology, Academia Sinica, Taiwan (1997-2002)

RESEARCH INTERESTS

With the changes of dietary habits and sedentary lifestyle in modern society, obesity and its serious comorbidities such as type 2 diabetes and non-alcoholic fatty liver disease are growing concern of public health. The mechanisms contributing to the occurrence, progression and treatment of metabolic diseases and discovery of new pharmacotherpies are the interest of the laboratory.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

The research activity includes identification and characterization of drug hits and leads by in vitro assay platforms, in vivo pharmacodynamic studies, in vivo efficacy disease animal models and mechanistic studies. Potential biomarkers associated with the drug targets and polypharmacology are also investigated. The previous effort has led to the identification of DBPR211. DBPR211 is a first-in-class drug candidate by antagonizing peripheral cannabinoid receptor 1 (CB1) and has the potential for treating metabolic disorders, including obesity, type 2 diabetes, non-alcoholic fatty liver disease, and fibrotic diseases. It received investigational new drug approval from both US and Taiwan Food and Drug Administrations.

HONORS & AWARDS

  • 2021            國家新創獎精進續獎
  • 2019            未來科技突破獎
  • 2017            未來科技突破獎
  • 2016            第十三屆國家新創獎 學研新創獎(生技製藥組、最佳產業效益獎)
  • 2016            NRPB個別型亮點計畫 (抗糖尿病新穎候選藥物: DBPR211)
  • 2003-2004  法國糖尿病協會研究獎學金

SELECTED PUBLICATIONS (from 2011)

  1. T. K. Yeh, J.S. Song, P.W. Chang, J.C. Yu, C.H. Chang, F.Y. Liao, Y.W. Tien, R. Kuppusamy, A.S. Li, C.H. Chen, C.W. Chen, L.M. Lin, H.H. Chang, C.H. Huang, J.Y. Yao, M.H. Wu, Y.H. Peng, C.C. Hsueh, W.C. Hsiao, P.H. Chen, C.Y. Lin, S.H. Hsieh, C. Shih, M.S. Hung*, S.Y. Wu*, C.C. Kuo* and S.H. Ueng*. Discovery and development of a novel N-(3-bromophenyl)- {[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design. Eur. J. Med. Chem. 229:114043, 2022.
  2. Y.H. Peng, F.Y. Liao, C.T. Tseng, R. Kuppusamy, A.S. Li, C.H. Chen, Y.S. Fan, S.Y. Wang, M.H. Wu, C. Shih, K.S. Shia, T.K. Yeh, M.S. Hung, C.C. Kuo, J.S. Song, S.Y. Wu, S.H. Ueng. Unique sulfur–aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 63:1642–1659, 2020.
  3. Y. N. Yeh, K.Y. Hsin, A. Zimmer, L.Y. Lin* and M.S. Hung*. A structure-function approach identifies L-PGDS as a mediator responsible for glucocorticoid-induced leptin expression in adipocytes. Biochem. Pharmacol. 166: 203-211, 2019.
  4. C.P. Chang, H.O. Huang, J.K. Huang, M.S. Hung, C.H. Wu, J.S. Song, C.J. Lee, C.S. Yu and K.S. Shia. Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist. Bioorg. Med. Chem. 27: 216-223, 2019.
  5. Y. H. Chen, H.J. Lee, M.T. Lee, Y.T. Wu, Y.H. Lee, L.L. Hwang, M.S. Hung, A. Zimmer, K. Mackie and L.C. Chiou. Median nerve stimulation induces analgesia via orexin-initiated endocannabinoid disinhibition in the periaqueductal gray. Proc. Natl. Acad. Sci. USA 115: E10720-E10729, 2018.
  6. W.C. Hsu, M.Y. Chen, S.C. Hsu, L.R. Huang, C.Y. Kao, W.H. Cheng, C.H. Pan, M.S. Wu, G.Y. Yu, M.S. Hung, C.M. Leu, T.H. Tan and Y.W. Su. DUSP6 mediates T cell receptor-engaged glycolysis and restrains TFH cell differentiation. Proc. Natl. Acad. Sci. USA 115: E8027-8036, 2018.
  7. S.Y. Lin, T.K. Yeh, J.S. Song, M.S. Hung, M.F. Cheng, F.Y. Liao, A.S. Li, S.Y. Cheng, L.M. Lin, C.H. Chiu, M.H. Chiu, M.H. Wu, Y.J. Lin, W. Hsiao, M. Sun, Y.H. Wang, C.H. Huang, Y.C. Tang, H.H. Chang, Z.T. Huang, Y.S. Chao, C. Shih, S.L. Pan, S.Y. Wu, C.C. Kuo, S.H. Ueng. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorg. Chem. 77: 600-607, 2018.
  8. C.C. Chang, C.Y. Chen, H.C. Wen, C.Y. Huang, M.S. Hung, H.C. Lu, W.L. Chen and C.H. Chang. Caveolin-1 secreted from adipose tissues and adipocytes functions as an adipogenesis enhancer. Obesity 25: 1932-1940, 2017.
  9. L.W. Tung, G.L. Lu, Y.H. Lee, L. Yu, H.J. Lee, E. Leishman, H. Bradshaw, L.L. Hwang, M.S. Hung, K. Mackie, A. Zimmer and L.C. Chiou. Orexins contribute to restraint stress-induced cocaine relapse by endocannabinoid-mediated disinhibition of dopaminergic neurons. Nat. Comm. 7: 12199, 2016.
  10. S.Y. Lin, T.K. Yeh, C.C. Kuo, J.S. Song, M.F. Cheng, F.Y. Liao, M.W. Chao, H.L. Huang, Y.L. Chen, C.Y. Yang, M.H. Wu, C.L. Hsieh, W. Hsiao, Y.H. Peng, J.S. Wu, L.M. Lin, M. Sun, Y.S. Chao, C. Shih, S.Y. Wu, S.L. Pan*, M.S. Hung* and S.H. Ueng*. Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy. J. Med. Chem. 59: 419-430, 2016. (*co-corresponding author)
  11. Y.H. Peng, S.H. Ueng, C.T. Tseng, M.S. Hung, J.S. Song, J.S. Wu, F.Y. Liao, Y.S. Fan, M.H. Wu, W.C. Hsiao, C.C. Hsueh, S.Y. Lin, C.Y. Cheng, C.H. Tu, L.C. Lee, M.F. Cheng, K.S. Shia, C. Shih, S. Wu. Important Hydrogen Bond Networks in Indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor Design revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. J. Med. Chem. 59: 282-293, 2016.
  12. J.S. Wu, S.Y. Lin, F.Y. Liao, W. Hsiao, L.C. Lee, Y.H. Peng, C.L. Hsieh, M.H. Wu, J.S. Song, A. Yueh, C.H. Chen, S.H. Yeh, C.Y. Liu, S.Y. Lin, T.K. Yeh, J.T. Hsu, C. Shih, S.H. Ueng*, M.S. Hung*, SY Wu*. Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening. J. Med. Chem. 58: 7807-7819, 2015. (*co-corresponding author)
  13. W.C. Hsiao, K.S. Shia, Y.T. Wang, Y.N. Yeh, C.P. Chang, Y. Lin, P.H. Chen, C.H. Wu, Y.-S. Chao and M.S. Hung*. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabet. Obe. Metab. 17: 495-504, 2015. (*corresponding author)
  14. M.F. Cheng #, M.S. Hung #, J.S. Song, S.Y. Lin, F.Y. Liao, M.H. Wu, W.C. Hsiao, C.L. Hsieh, J.S. Wu, Y.S. Chao, C. Shih, S.Y. Wu, and S.H. Ueng. Discovery and structure–activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. Bioorg. Med. Chem. Let. 24: 3403-3406 (2014).
  15. C.P. Chang, C.H. Wu, J.S. Song, M.C. Chou, Y.C. Wong, Y. Lin, T.K. Yeh, A.A. Sadani, M.H. Ou, K.H. Chen, P.H. Chen, P.C. Kou, C.T. Tseng, K.H. Chang, S.L. Tseng, Y.S. Chao, M.S. Hung* and K.S. Shia*. Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5- (5-((4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in DIO Mice. J. Med. Chem. 56: 9920-9933, 2013. (*co-corresponding author)
  16. H.W. Chen, H.Y. Chen, L.T. Wang, F.H. Wang, L.W. Fang, H.Y. Lai, H.H. Chen, J. Lu, M.S. Hung, Y. Cheng, M.Y. Chen, S.J. Liu, P. Chong, O.K.S. Lee, and S.C. Hsu. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J. Immunol. 190: 5065-5077, 2013.
  17. R.S. Vijayakumar, Y. Lin, K.S. Shia, Y.N. Yeh, W.P. Hsieh, W.C. Hsiao, C.P. Chang, Y.S. Chao, and M.S. Hung*. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis, and reduces cardiometabolic risk factors. Int. J. Obesity 36: 999-1006, 2012 (*corresponding author)
  18. Y.K. Wu, C.F. Yeh, T.W. Ly and M.S. Hung*. A new perspective of cannabinoid 1 receptor antagonists: Approaches toward peripheral CB1 blockers without crossing the blood-brain barrier. Curr. Top. Med. Chem. 11: 1421-1429, 2011. (*corresponding author)
  19. C.H. Yao, J.S. Song, C.T. Chen, T.K. Yeh, M.S. Hung, C.C. Chang, Y.W. Liu, M.C. Yuan, C.J. Hsieh, C.Y. Huang, M.H. Wang, C.H. Chiu, T.C. Hsieh, S.H. Wu, W.C. Hsiao, K.F. Chu, C.H. Tsai, Y.S. Chao and J.C. Lee. Discovery of Novel N-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes. J. Med. Chem. 54: 166-178, 2011.

Comments are closed.